Rituximab for Scleroderma: Does Something Finally Work? PDF Print E-mail
Tuesday, 06 April 2010 20:37
Kevin Deane, MD
Posted: 03/10/2010

Experience With Rituximab in Scleroderma: Results From a 1-Year, Proof-of-Principle Study
Daoussis D, Liossis SN, Tsamandas AC, et al. Rheumatology (Oxford). 2010;49:271-280

Background
Multiple drugs have been tried in scleroderma to improve both skin disease and pulmonary disease. However, most of these studies have failed to show significant benefit. In an open-label study, Daoussis and colleagues investigated the effect of the B-cell directed agent rituximab in improving pulmonary function and skin disease in scleroderma.

Study Summary
Eight patients with scleroderma were given rituximab for 2 cycles 24 weeks apart; each cycle consisted of 375 mg/m2 weekly, for a total of 4 doses. Lung and skin measures at baseline and 1 year after treatment were compared within the group of treated patients and with results in 6 patients with scleroderma treated with other agents, including mycophenolate, corticosteroids, cyclophosphamide, and bosentan (patients receiving rituximab may have also given these agents). All patients had diffuse scleroderma, were Scl-70 positive, and had clinically significant interstitial lung disease.

The rituximab-treated patients had improvement in forced vital capacity and diffusing carbon monoxide compared with their baseline values and compared with controls. Functional status also improved in 6 rituximab-treated patients, with a decrease in Health Assessment Questionnaire score of 0.2. Finally, skin thickening improved in rituximab-treated patients compared with their baseline status, and in several patients, skin fibrosis on skin biopsy was reduced. No mortality benefit was reported. The authors conclude that rituximab may improve lung function and skin scores in patients with scleroderma, and they propose larger randomized studies to investigate further the role of rituximab in treatment of scleroderma.

Viewpoint
The failure of multiple treatments to show clinically meaningful and statistically significant improvement in scleroderma has been frustrating for those who treat this devastating disease. Evidence that B cells may be important in the pathogenesis of scleroderma[1] has served as the rationale for Daoussis and colleagues’ study, and their results are promising. However, the sample was small, and we need to be cautious in terms of how much excitement the findings generate. As the authors rightly point out, their study should serve to stimulate large, randomized placebo-controlled trials for scleroderma and stimulate further investigation into the role of B cells in the pathogenesis of this disease. Of importance will be which outcomes are assessed in future studies. Improvements in measures of lung physiology are important, but ultimately quality of life and mortality need to improve.

References
1. Lafyatis R, O'Hara C, Feghali-Bostwick CA, Matteson E. B cell infiltration in systemic sclerosis-associated interstitial lung disease. Arthritis Rheum. 2007;56:3167-3168.
 
More articles :

» Platelet Gel In The Treatment Of Severe Scleroderma Skin Ulcers

Dilia Giuggioli, Michele Colaci, Andreina Manfredi, Mariateresa Mariano and Clodoveo FerriSystemic sclerosis (SSc) is characterized by microvascular damage and fibrosis of the skin and internal organs. Non-healing skin ulcers, mainly non-venous leg...

» A Brief History of Scleroderma

While scleroderma may not be very well known to the average person, investigation reveals it has been around for a long time.Classical ReferencesCases of skin disease similar to scleroderma may be found in the writings of Hippocrates as far back as...

» A Scleroderma Fact Sheet

Below, is a very useful fact sheet on Scleroderma. Making for much easier reading and reference, this fact sheet highlights what Scleroderma is, how is it diagnosed, who gets it, complications which may arise, and how it can be treated. Feel free to...

» Oral Health of Chinese People with Systemic Sclerosis

Clive M. K. Yeung; Ian A. Lai; C. H. Chu; W. Keung Leung; Mo Yin MokThe University of Hong KongReceived: 22 July 2010 / Accepted: 28 September 2010 / Published online: 12 October 2010Scleroderma is a symptom of a group of diseases that involve the...

» Pulsed High-Dose Corticosteroids Combined With Low-Dose Methotrexate in Severe Localized Scleroderma

Alexander Kreuter, MD; Thilo Gambichler, MD; Frank Breuckmann, MD; Sebastian Rotterdam, MD; Marcus Freitag, MD; Markus Stuecker, MD; Klaus Hoffmann, MD; Peter Altmeyer, MDArch Dermatol. 2005;141:847-852Objective: To evaluate the efficacy of pulsed...

» The Vascular Microenvironment and Systemic Sclerosis

Tracy Frech, Nathan Hatton, Boaz Markewitz, Mary Beth Scholand, Richard Cawthon, Amit Patel, and Allen SawitzkeReceived 5 April 2010; Revised 28 May 2010; Accepted 6 July 2010The role of the vascular microenvironment in the pathogenesis Systemic...